Results 141 to 150 of about 15,879 (168)

Oligometastatic Prostate Cancer: Clues from an N-of-1. [PDF]

J Clin Med
Kirschenbaum A, Verma P, Cheung P, Yao S, Drummond C, Tipi I, Yao A, Levine AC.   +7 more
europepmc   +1 more source

NF-κB Signaling in Prostate Cancer Progression: Inflammatory Mediators, Survival Pathways, and Regulatory Axes. [PDF]

Cancers (Basel)
Al-Hakm R, Altaie AM, Boghossian A, Bendardaf R, Talaat IM, Hamoudi R.   +5 more
europepmc   +1 more source

Treatment Patterns and Attrition in Metastatic Castration-Resistant Prostate Cancer.

JAMA Netw Open
Hooper G, Jo Y, Nandakumar V, Gebrael G, Ozay ZI, Ostrowski M, Hardy T, Lin E, Campbell P, Murdock EG, Upadhyay L, Goel K, Thomas VM, Li H, Sokolova AO, Swami U, Agarwal N.   +16 more
europepmc   +1 more source

Efficacy and toxicity of low-doses versus standard-dose enzalutamide in advanced prostate cancer: a real-world study with implications for cancer prevention/interception. [PDF]

BMC Cancer
Oliva M, Boitano M, Carbone A, Briata IM, Webber TB, Corradengo D, Introini C, Puntoni M, Ennas M, Germinale F, Provinciali N, Clavarezza M, Gozza A, Defferrari C, D'Amico M, Parnes HL, DeCensi A.   +16 more
europepmc   +1 more source

Myosteatosis Predicts Poor Prognosis in Patients With Castration-Resistant Prostate Cancer Treated With Enzalutamide. [PDF]

Int J Urol
Kanaki T, Hatano K, Oka T, Tani M, Konishi M, Liu Y, Horitani H, Matsukawa A, Inoguchi S, Yoshimura A, Horibe Y, Sassi N, Okuda Y, Ishizuya Y, Hayashi T, Yamamoto Y, Kato T, Kawashima A, Nonomura N.   +18 more
europepmc   +1 more source

The Role of Nuclear Medicine in Prostate Cancer. [PDF]

Diagnostics (Basel)
Grozdic Milojevic I, Milojevic B, Skrijelj D, Bumbasirevic U, Janicic A, Kajmakovic B, Sobic-Saranovic D, Artiko V, Beatovic S.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Therapy-Related Myeloid Neoplasms After [¹⁷⁷Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series

Journal of Nuclear Medicine
[177Lu]Lu-prostate-specific membrane antigen (PSMA) therapy has a favorable toxicity profile in patients with metastatic castration-resistant prostate cancer (mCRPC). Therapy-related myeloid neoplasm (t-MN) has been described after [177Lu]Lu-DOTATATE but has not, to our knowledge, yet been reported after [177Lu]Lu-PSMA.
Michal, Eifer, Duncan E K, Sutherland, Isaac, Goncalves, James P, Buteau, Lewis, Au, Arun A, Azad, Louise, Emmett, Grace, Kong, Louise, Kostos, Aravind S, Ravi Kumar, Edmond M, Kwan, Elizabeth, Medhurst, Shahneen, Sandhu, Ben, Tran, Alexander W, Wyatt, Michael S, Hofman   +15 more
openaire   +2 more sources

Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer

Journal of Urology, 2021
, Rajeev Ayyagari, Susan Halabi
exaly  

Distinct Response to Platinum-Based Chemotherapy among Patients with Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination

Journal of Urology, 2021
Fan Liancheng, Baijun Dong, Yanqing Wang   +2 more
exaly